23andMe: Five Things from 2018
Before we kick off the New Year, let’s look back and highlight a few important moments for us here at 23andMe in 2018.The Power of Big DataFor some types of...
Read More
23andMe Granted The First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetics Reports
The U.S. Food and Drug Administration (FDA) granted 23andMe authorization to offer reports to customers on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.
Read More
Learn More About 23andMe’s New Genetic Health Risk Reports
23andMe recently started offering customers new Genetic Health Risk reports that have received FDA authorization. Below we’ve highlighted some important features in these reports to help you get more out...
Read More
The FDA Wants To Hear Your Opinion
If you have an opinion about genetic testing and the best way to return those results, the U.S. Food and Drug Administration (FDA) wants to hear it at a daylong...
Read More
This Year’s Top Ten Stories in Genetics
Starting in January with the launch of the ambitious Precision Medicine Initiative in the United States, 2015 finished with a heated debate around the appropriate use of technology that allows...
Read More
A New 23andMe Experience
23andMe made some news today, with the launch of a new experience for customers that includes the first and only direct-to-consumer genetic service that meets U.S. FDA standards. We invested nearly...
Read More
Patients Perspective on Parkinson’s Disease
As federal regulators listened, patients told them of their symptoms – the sleepless nights, the days with uncontrollable tremors or the little struggles simply maintaining their balance. Paul Cannon, 23andMe’s...
Read More
Live Long And Prosper
We all measure our age in years, but results of a study lead by researchers at Kings College in London found what may be a better measurement of age –...
Read More
A Note to Our Customers Regarding the FDA
By Anne Wojcicki Today, 23andMe was granted authorization by the U.S. Food and Drug Administration (FDA) to market the Bloom syndrome carrier status report. This is an important first step...
Read More
What The FDA Decision Means For 23andMe Customers
What does getting this marketing authorization mean for existing and future customers? As the first direct to consumer genetic test to complete the regulatory pathway, 23andMe’s Bloom Syndrome Carrier Status...
Read More